Press releases
- In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action
- Invitation to the presentation of Calliditas´s interim report January - March 2024
- Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
- Notice of annual general meeting of Calliditas Therapeutics AB (publ)
- Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
- Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
- Calliditas Therapeutics' 2023 Annual Report Published
- Calliditas Announces Positive NefIgArd Open Label Extension Results
- Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
- Calliditas Therapeutics to Attend Conferences in April
More ▼
Key statistics
On Tuesday, Calliditas Therapeutics AB (LC8:DEU) closed at 9.99, 43.23% above the 52 week low of 6.98 set on Sep 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.06 |
---|---|
High | 10.13 |
Low | 9.85 |
Bid | 9.95 |
Offer | 10.04 |
Previous close | 9.96 |
Average volume | 238.44 |
---|---|
Shares outstanding | 59.58m |
Free float | 49.57m |
P/E (TTM) | -- |
Market cap | 6.91bn SEK |
EPS (TTM) | -8.69 SEK |
Data delayed at least 15 minutes, as of May 21 2024.
More ▼